ASCLETIS-B (01672) Surges Over 4% as New Drug Denifanstat Tablet's Marketing Application Accepted

Stock News12-08

ASCLETIS-B (01672) rose more than 4%, reaching HK$14.23 by the time of writing, with a trading volume of HK$26.83 million. On December 4, the CDE website showed that the marketing application for ASCLETIS's Class 1 new drug, Denifanstat tablets, had been accepted. Based on the drug's clinical research progress, Insight Database speculates that the intended indication is for moderate-to-severe acne vulgaris treatment.

Denifanstat (ASC40) is a potential first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor. Originally developed by Sagimet Biosciences, ASCLETIS holds exclusive rights to the drug in Greater China.

Cinda Securities previously noted that ASCLETIS continues to invest in the weight-loss and metabolic field, focusing on core challenges with a deep pipeline layout. With potential Phase II data readouts for small-molecule GLP-1R agonists and further progress in the THRβ pipeline, the company is expected to maintain a differentiated competitive edge in the weight-loss sector. Additionally, the acne treatment drug ASC40, introduced by the company, is anticipated to gradually contribute to revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109198656?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 13:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109198656","market":"hk","top_or_hot":-1,"title":"ASCLETIS-B (01672) Surges Over 4% as New Drug Denifanstat Tablet's Marketing Application Accepted","media":"Stock News","content":"<p>ASCLETIS-B (01672) rose more than 4%, reaching HK$14.23 by the time of writing, with a trading volume of HK$26.83 million. On December 4, the CDE website showed that the marketing application for ASCLETIS's Class 1 new drug, Denifanstat tablets, had been accepted. Based on the drug's clinical research progress, Insight Database speculates that the intended indication is for moderate-to-severe acne vulgaris treatment.</p>\n<p>Denifanstat (ASC40) is a potential first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor. Originally developed by Sagimet Biosciences, ASCLETIS holds exclusive rights to the drug in Greater China.</p>\n<p>Cinda Securities previously noted that ASCLETIS continues to invest in the weight-loss and metabolic field, focusing on core challenges with a deep pipeline layout. With potential Phase II data readouts for small-molecule GLP-1R agonists and further progress in the THRβ pipeline, the company is expected to maintain a differentiated competitive edge in the weight-loss sector. Additionally, the acne treatment drug ASC40, introduced by the company, is anticipated to gradually contribute to revenue.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B (01672) Surges Over 4% as New Drug Denifanstat Tablet's Marketing Application Accepted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B (01672) Surges Over 4% as New Drug Denifanstat Tablet's Marketing Application Accepted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 13:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) rose more than 4%, reaching HK$14.23 by the time of writing, with a trading volume of HK$26.83 million. On December 4, the CDE website showed that the marketing application for ASCLETIS's Class 1 new drug, Denifanstat tablets, had been accepted. Based on the drug's clinical research progress, Insight Database speculates that the intended indication is for moderate-to-severe acne vulgaris treatment.</p>\n<p>Denifanstat (ASC40) is a potential first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor. Originally developed by Sagimet Biosciences, ASCLETIS holds exclusive rights to the drug in Greater China.</p>\n<p>Cinda Securities previously noted that ASCLETIS continues to invest in the weight-loss and metabolic field, focusing on core challenges with a deep pipeline layout. With potential Phase II data readouts for small-molecule GLP-1R agonists and further progress in the THRβ pipeline, the company is expected to maintain a differentiated competitive edge in the weight-loss sector. Additionally, the acne treatment drug ASC40, introduced by the company, is anticipated to gradually contribute to revenue.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1109198656","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109198656","pubTimestamp":1765172858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) rose more than 4%, reaching HK$14.23 by the time of writing, with a trading volume of HK$26.83 million. On December 4, the CDE website showed that the marketing application for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","BK1161":"生物科技","BK1574":"生物医药B类股","01477":"欧康维视生物-B","01672":"歌礼制药-B"},"translate_title":"歌礼-B(01672)大涨超4%，新药地尼凡他片上市申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1,"01477":1},"content_text":"ASCLETIS-B (01672) rose more than 4%, reaching HK$14.23 by the time of writing, with a trading volume of HK$26.83 million. On December 4, the CDE website showed that the marketing application for ASCLETIS's Class 1 new drug, Denifanstat tablets, had been accepted. Based on the drug's clinical research progress, Insight Database speculates that the intended indication is for moderate-to-severe acne vulgaris treatment.\nDenifanstat (ASC40) is a potential first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor. Originally developed by Sagimet Biosciences, ASCLETIS holds exclusive rights to the drug in Greater China.\nCinda Securities previously noted that ASCLETIS continues to invest in the weight-loss and metabolic field, focusing on core challenges with a deep pipeline layout. With potential Phase II data readouts for small-molecule GLP-1R agonists and further progress in the THRβ pipeline, the company is expected to maintain a differentiated competitive edge in the weight-loss sector. Additionally, the acne treatment drug ASC40, introduced by the company, is anticipated to gradually contribute to revenue.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109198656","isCrawlerRequest":true}